Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation

Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation

Hematopoietic growth factors have been shown to be effective in reducing the period of neutropenia after autologous bone marrow transplantation (BMT). Initial concerns over potential aggravation of graft-versus-host disease (GVHD) and increase in the incidence of relapse in patients with myeloid leukemias influenced the number of studies using hematopoietic growth factors after allogeneic BMT. ...

Recombinant human granulocyte colony-stimulating factor after allogeneic bone marrow transplantation.

OBJECTIVE To examine the effect of rhG-CSF on allogeneic bone marrow transplantation. PATIENTS AND METHODS One hundred and twenty patients with acute or chronic leukemia received HLA-A.B.DR identical and MLC negative sibling donor allo-BMT. Among them, 58 cases of were treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF), while the other 62 cases of the 120 patients ...

Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation.

Hematopoietic growth factors have shown clinical benefits in patients undergoing chemotherapy and stem cell transplantation, but few studies have been performed to assess whether the benefits are worth the costs. We reviewed 196 patients undergoing T-cell depleted related donor bone marrow transplantation (BMT) between 1990 and 1996 to assess the effect of growth factor use on time to engraftme...

Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation.

Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation.

In a prospective randomized study, five European transplant centers compared recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; mammalian glycosylated) with placebo. rhGM-CSF was administered in a dose of 8 micrograms glycoprotein (5.5 micrograms protein)/kg/d, as a continuous intravenous (IV) infusion for 14 days, starting 3 hours after bone marrow infusion. Fifty-se...